Evidence map›Paper›PMID 25870276›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain.

Pragnesh Mistry, Michelle H W Laird, Ryan S Schwarz, Shannon Greene, Tristan Dyson, Greg A Snyder, Tsan Sam Xiao, Jay Chauhan, Steven Fletcher, Vladimir Y Toshchakov and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 170 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Characterization of a New AG-II-like Glycoprotein fromCurrent issues in molecular biology · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. IntratumoralAnimals : an open access journal from MDPI · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Pragnesh MistryDepartment of Microbiology and Immunology and.
Michelle H W LairdDepartment of Microbiology and Immunology and.
Ryan S SchwarzDepartment of Microbiology and Immunology and.
Shannon GreeneDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201; and.
Tristan DysonDepartment of Microbiology and Immunology and.
Greg A SnyderInstitute of Human Virology, School of Medicine, University of Maryland, Baltimore (UMB), Baltimore, MD 21201;
Tsan Sam XiaoDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106.
Jay ChauhanDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201; and.
Steven FletcherDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201; and.
Vladimir Y ToshchakovDepartment of Microbiology and Immunology and.
Alexander D MacKerellDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201; and svogel@som.umaryland.edu amackere@rx.umaryland.edu.
Stefanie N VogelDepartment of Microbiology and Immunology and svogel@som.umaryland.edu amackere@rx.umaryland.edu.
Bipar · FRUniversity of Maryland, Baltimore · USCase Western Reserve University · US

Funding

DIFFERENTIATIVE SIGNALS FOR MACROPHAGE ACTIVATIONR37AI018797 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI VOGEL, STEFANIE N. · 2000 to 2009
$5.3M
DIFFERENTIATIVE SIGNALS FOR MACROPHANGE ACTIVATIONR01AI018797 · NIAID · U.S. UNIFORMED SERVICES UNIV OF HLTH SCI · PI VOGEL, STEFANIE N. · 1985 to 2014
$3.8M
Training in Molecular and Mechanistic ToxicologyT32ES007263 · NIEHS · UNIVERSITY OF MARYLAND BALTIMORE · PI ALBUQUERQUE, EDSON X · 1990 to 2012
$2.4M
Differentiative Signals for Macrophage ActivationR56AI018797 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI VOGEL, STEFANIE N. · 2015 to 2015
$506k
Therapeutic targeting of the B-cell lymphoma associated mutation MYD88-L265PR21CA191726 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI SNYDER, GREG ALLEN · 2015 to 2016
$395k
NCI NIH HHS R21 CA191726NIAID NIH HHS AI018797NIAID NIH HHS R01 AI018797NIAID NIH HHS R37 AI018797NIAID NIH HHS R56 AI018797NIEHS NIH HHS T32 ES007263NIEHS NIH HHS T32ES007263
6 · The paper itself

Abstract

Toll-like receptor (TLR) signaling is initiated by dimerization of intracellular Toll/IL-1 receptor resistance (TIR) domains. For all TLRs except TLR3, recruitment of the adapter, myeloid differentiation primary response gene 88 (MyD88), to TLR TIR domains results in downstream signaling culminating in proinflammatory cytokine production. Therefore, blocking TLR TIR dimerization may ameliorate TLR2-mediated hyperinflammatory states. The BB loop within the TLR TIR domain is critical for mediating certain protein-protein interactions. Examination of the human TLR2 TIR domain crystal structure revealed a pocket adjacent to the highly conserved P681 and G682 BB loop residues. Using computer-aided drug design (CADD), we sought to identify a small molecule inhibitor(s) that would fit within this pocket and potentially disrupt TLR2 signaling. In silico screening identified 149 compounds and 20 US Food and Drug Administration-approved drugs based on their predicted ability to bind in the BB loop pocket. These compounds were screened in HEK293T-TLR2 transfectants for the ability to inhibit TLR2-mediated IL-8 mRNA. C16H15NO4 (C29) was identified as a potential TLR2 inhibitor. C29, and its derivative, ortho-vanillin (o-vanillin), inhibited TLR2/1 and TLR2/6 signaling induced by synthetic and bacterial TLR2 agonists in human HEK-TLR2 and THP-1 cells, but only TLR2/1 signaling in murine macrophages. C29 failed to inhibit signaling induced by other TLR agonists and TNF-α. Mutagenesis of BB loop pocket residues revealed an indispensable role for TLR2/1, but not TLR2/6, signaling, suggesting divergent roles. Mice treated with o-vanillin exhibited reduced TLR2-induced inflammation. Our data provide proof of principle that targeting the BB loop pocket is an effective approach for identification of TLR2 signaling inhibitors.

Indexed as

Anti-Inflammatory AgentsBenzaldehydesAnimalsAntioxidantsDrug DesignDrug Evaluation, PreclinicalHEK293 CellsHumansInflammationInterleukin-8MiceProtein Structure, TertiaryRNA, MessengerSignal TransductionToll-Like Receptor 1Toll-Like Receptor 2Anti-Inflammatory AgentsAntioxidantsBenzaldehydesCXCL8 protein, humanInterleukin-8RNA, MessengerTLR2 protein, humanTlr2 protein, mouseTLR6 protein, humanTlr6 protein, mouseToll-Like Receptor 1Toll-Like Receptor 2Toll-Like Receptor 6vanillinBB loopCADDsmall molecule inhibitorTLR2 pocket

Identifiers

PMID25870276
PMCPMC4418912
OpenAlexW1964947310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.